Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.22
+2.5%		$0.99
$0.74
▼
$1.74
$38.36M0.05149,039 shs146,206 shs
Celularity, Inc. stock logo
CELU
Celularity
$1.31
+3.1%		$1.02
$0.56
▼
$2.55
$37.92M0.7912.26 million shs188,246 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$4.14
$5.15
$0.72
▼
$20.32
$39.91M1.0565,254 shs41,394 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$0.24
+2.7%		$0.25
$0.20
▼
$5.14
$10.65M0.39426,941 shs718,217 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%-12.86%+8.93%+18.45%-24.22%
Celularity, Inc. stock logo
CELU
Celularity
0.00%-7.09%+70.80%+74.13%-39.07%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%-2.13%-13.03%-43.67%+73.22%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%0.00%-0.46%-64.19%-91.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.22
+2.5%		$0.99
$0.74
▼
$1.74
$38.36M0.05149,039 shs146,206 shs
Celularity, Inc. stock logo
CELU
Celularity
$1.31
+3.1%		$1.02
$0.56
▼
$2.55
$37.92M0.7912.26 million shs188,246 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$4.14
$5.15
$0.72
▼
$20.32
$39.91M1.0565,254 shs41,394 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$0.24
+2.7%		$0.25
$0.20
▼
$5.14
$10.65M0.39426,941 shs718,217 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%-12.86%+8.93%+18.45%-24.22%
Celularity, Inc. stock logo
CELU
Celularity
0.00%-7.09%+70.80%+74.13%-39.07%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%-2.13%-13.03%-43.67%+73.22%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%0.00%-0.46%-64.19%-91.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$5.00309.84% Upside
Celularity, Inc. stock logo
CELU
Celularity
1.00
SellN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
2.67
Moderate Buy$5.0020.77% Upside
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.80
Reduce$0.95295.83% Upside

Current Analyst Ratings Breakdown

Latest VTGN, ATNM, CELU, and EDSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/27/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/5/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/6/2026
Celularity, Inc. stock logo
CELU
Celularity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/29/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M1.09N/AN/A$1.31 per share0.93
Celularity, Inc. stock logo
CELU
Celularity
$26.55M1.43N/AN/A($1.32) per share-0.99
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.45 per shareN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$1.27M8.39N/AN/A$0.90 per share0.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.36N/AN/AN/AN/A-100.85%-47.89%N/A
Celularity, Inc. stock logo
CELU
Celularity
-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%11/13/2026 (Estimated)
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$7.19M-$1.69N/AN/AN/AN/A-560.22%-105.74%N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$69.68M-$1.66N/AN/AN/A-2,702.64%-152.59%-117.45%11/12/2026 (Estimated)

Latest VTGN, ATNM, CELU, and EDSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q1 2027
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.3650-$0.30+$0.0650-$0.30$0.50 million$1.48 million
8/13/2026Q3 2026
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.4350-$0.60-$0.1650-$0.60N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Celularity, Inc. stock logo
CELU
Celularity
N/A
0.15
0.15
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
2.76
2.76
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
3.07
3.07

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.60%
Celularity, Inc. stock logo
CELU
Celularity
17.30%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
24.40%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
2.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2531.44 million29.32 millionOptionable
Celularity, Inc. stock logo
CELU
Celularity
11528.95 million23.94 millionOptionable
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
179.64 million7.29 millionNot Optionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4144.38 million43.08 millionOptionable

Recent News About These Companies

VistaGen Stockholders Reaffirm Board, Governance and Oversight
September 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vistagen-stockholders-reaffirm-board-governance-and-oversight?utm_source=marketbeat.com&utm_medium=referral
Vistagen to Present at Psych Congress 2026
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359489/0/en/vistagen-to-present-at-psych-congress-2026.html
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345334/0/en/vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update.html
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340279/0/en/vistagen-announces-topline-results-for-repeat-dose-study-of-fasedienol-for-acute-treatment-of-social-anxiety-disorder.html
SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics
August 4, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/srx-global-nyse-american-srxh-acquires-stake-in-vistagen-therapeutics-1036407545
Vistagen Appoints Douglas J. Williamson to its Board of Directors
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336795/0/en/vistagen-appoints-douglas-j-williamson-to-its-board-of-directors.html
Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)
July 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VTGN/pressreleases/3154507/stifel-nicolaus-remains-a-hold-on-vistagen-therapeutics-vtgn/
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
July 15, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-vistagen-therapeutics-inc-vtgn-stock-facing-new-challenges-after-palisade-4-clinical-trial-results-1801646/
VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst
July 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VTGN/pressreleases/3092835/vistagen-therapeutics-vtgn-receives-a-rating-update-from-a-top-analyst/
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
June 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918929-vistagen-therapeutics-inc-vtgn-discusses-palisademinus-4-phase-iii-results-and-post-hoc
Vistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummet
June 30, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/vistagens-anxiety-disorder-drug-misses-main-goal-late-stage-trial-shares-plummet-2026-06-30/
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vistagen-therapeutics-2026-workforce-cuts-raise-execution-risks-and-threaten-long-term-growth?utm_source=marketbeat.com&utm_medium=referral
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
June 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260615159406/en/Vistagen-Reports-Fiscal-Year-2026-Financial-Results-and-Provides-Corporate-Update/
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260609888048/en/Vistagen-Achieves-Minimum-ICH-Safety-Exposure-Recommendations-Across-Clinical-Program-for-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder/
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
June 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519798012/en/vistagen-appoints-angel-s.-angelov-md-mba-as-chief-medical-officer/
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
May 19, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-vistagen-therapeutics-inc-vtgn-a-breakout-anxiety-drug-stock-after-new-phase-3-extension-results-1764536/
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512521110/en/Vistagen-Announces-Preliminary-Positive-Data-in-Ongoing-Open-Label-Extension-Portion-of-PALISADE-3-Phase-3-Study-of-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder/
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
May 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260508181101/en/Vistagen-Announces-Completion-of-Last-Patient-Visit-in-PALISADE-4-Phase-3-Public-Speaking-Challenge-Study-of-Fasedienol-for-Acute-Treatment-of-Social-Anxiety-Disorder/
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3284191/0/en/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.22 +0.03 (+2.52%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.23 +0.01 (+0.82%)
As of 09/18/2026 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Celularity stock logo

Celularity NASDAQ:CELU

$1.31 +0.04 (+3.15%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.32 +0.00 (+0.38%)
As of 09/18/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$4.14 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$4.10 -0.04 (-1.09%)
As of 09/18/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$0.24 +0.01 (+2.74%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.24 +0.01 (+2.08%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas